Drug Release

Rationale for Prodrug Design

A large number of the new molecular entities with promising therapeutic profiles are dropped from the screening stage because of their inferior physicochemical and biopharmaceutical properties. These undesired properties result in poor absorption, extensive metabolism, and low bioavailability because of physical, biological, or metabolic barriers. If the chemical structure of the drug or lead compound can be modified to overcome these barriers and then revert to the pharmacologically active...